New Study Finds Jeuveau Injections Work Best For This Age Group

New Study Finds Jeuveau Injections Work Best For This Age Group featured image
Photo Credits: Model Used for Illustrative Purpose Only

In a recent survey published in Dermatologic Surgery, injectable wrinkle-relaxing treatment Jeuveau was shown to be more effective in both millennial and non-millennial patients with moderate to severe glabellar lines, however millennials reported the highest rate of satisfaction than any other group.

When it comes to treating the number 11 lines, or glabellar lines between the brows, the sooner you start, the better. Once those lines start to set in and become too deep, it’s very hard to iron them out completely. This is a good reason why those aged 25-40 are embracing prejuvenation and having their forehead and frown lines treated early on. While this group is known for worrying about aging early on, they’re also inclined to do something about it.

“As the largest and fastest-growing demographic today, the millennial consumer represents the single most important growth driver of the aesthetics industry,” said David Moatazedi, President and CEO of Evolus. “This younger generation is increasingly incorporating aesthetic neurotoxin treatment into their everyday beauty regimen, and we believe the findings of this analysis validate our millennial-focused strategy and will encourage broader adoption of Jeuveau among this important demographic.”

The Results

According to the study findings, of the 737 patients who were treated with a single dose of Jeuveau, millennials achieved “higher results across all effectiveness measurements and time periods.” Charlotte, NC dermatologist Gilly Munavalli, MD says the study results are similar to what he’s seeing at his practice. “I think this data mirrors real world findings. My millennial patients are quite satisfied with Jeuveau treatments and consider them safe, effective and a good cost value,” he notes.  

Omaha, NE dermatologist Joel Schlessinger, MD adds that the injectable is a perfect choice for this age group: “It provides a fresh look and allows them to dip their toes in the water with a treatment that works nicely, without being overpowering or overdone in look. I use it for many of my millennial patients and they love it!”

“Millennials are into prevention and prejuvenation,” shares Vancouver ophthalmologist Jean Carruthers, who pioneered the use of botulinum toxin in the late 1980s. “The improved results with neurotoxins seen in millennials compared to more mature subjects relates to there being less cutaneous change due to sun damage and intrinsic aging changes in this younger cohort,” she says.

The Timeline Factor

One other key takeaway from the study is the overwhelming satisfaction by consumers in this age range during onset and a month into the treatment as 100 percent reported being satisfied or very satisfied on days 7 and 30. While non-millennials also reported satisfying results, the 25-40 age bracket, who continue to be a driving force in aesthetics, were most impressed. “These findings make sense to me,” shares New York dermatologist Jody Levine, MD. “The lines of the younger patients have had less time to form and scar down. Hence it makes sense that glabellar lines of millennials will respond quicker and more effectively to neurotoxin than those of older patients.”

“The structural integrity of younger skin and its underlying components are simply healthier, stronger, and better able to support any treatment delivered to them,” shares Bloomfield Hills, MI dermatologist Linda C. Honet, MD. In the case of neurotoxin, she adds that injections into more robust facial muscles will understandably respond better and more efficiently. “It will also have the more intact cutaneous and subcutaneous support of the healthier components that give structural integrity to the face,” shares Dr. Honet.

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.